NEWARK, Del. — The global Precision Transplant Medicine Market is valued at USD 1,015.6 million in 2026 and is projected to reach USD 2,018.0 million by 2036, expanding at a 7.1% CAGR from 2026 to 2036. Demand is supported by recurring transplant decisions requiring compatibility assessment and longitudinal graft surveillance. In January 2025, the U.S. Health Resources and Services Administration (HRSA) reported 48,149 organ transplants in the United States during 2024, creating recurring demand for transplant diagnostics across compatibility assessment and molecular rejection surveillance.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-34110

Global Segment Leaders

• Organ Type — Kidney transplantation: 35.2% share in 2026. Kidney transplantation leads because of its larger procedure base and recurring surveillance requirements.
• Application — Donor-recipient matching: 37.6% share in 2026. The segment leads because matching directly affects organ allocation and immediate transplant feasibility.
• Technology — Genomic profiling: 36.4% share in 2026. High-resolution compatibility and biomarker assessment workflows support the segment's leading position.
• End User — Transplant centers: 35.6% share in 2026. Transplant centers control multidisciplinary clinical decisions, protocol design, and clinical escalation across transplant pathways.

Country-Level Performance

The country CAGRs and country-level developments above are published on the FMI report page.

Regional Context

Higher-growth markets: South Korea and the UK record the two highest published country CAGRs at 8.3% and 7.8%, respectively. FMI attributes South Korea's growth to strong digital infrastructure and centralized coordination, while the UK's national transplant system concentrates specialist protocols, purchasing decisions, and training within NHS institutions.

Intermediate-growth market: Germany records a 7.4% CAGR, supported by established transplant coordination through regional centers and Eurotransplant allocation structures. The country also has concentrated specialist institutions supporting histocompatibility and molecular surveillance services.

Lower-growth markets within the profiled group: The USA and Japan record CAGRs of 6.4% and 6.2%. FMI links U.S. growth to its large specialist transplant-care base while noting variable payer coverage and documentation requirements. Japan's market operates through approved specialist hospitals and hub relationships, with longer service distances and limited procedure volumes outside major metropolitan centers affecting commercial support.

The full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with analysis across 30+ countries.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-34110

Competitive Landscape

Key companies profiled in the Precision Transplant Medicine Market are CareDx, Thermo Fisher Scientific, Natera, GenDx, Werfen, HistoGenetics, QIAGEN, and Eurofins Viracor. Competition spans transplant-specific molecular monitoring, HLA typing and matching, sequencing, histocompatibility testing, reference laboratory services, and interpretation and workflow support. CareDx and Natera focus on molecular rejection monitoring, Thermo Fisher Scientific, GenDx, and Werfen provide HLA typing and transplant laboratory platforms, while QIAGEN and HistoGenetics participate through sequencing and specialist histocompatibility capabilities.

Recent developments include Natera and Eledon selecting Prospera as the exclusive donor-derived cell-free DNA assay for a planned Phase 3 kidney transplant trial in June 2026. The planned study is expected to enroll approximately 600 recipients across more than 100 centers. In March 2025, CareDx expanded commercial AlloSure testing to pediatric heart recipients of every age and patients receiving simultaneous pancreas-kidney transplants.

In July 2025, QIAGEN launched QIAseq xHYB Long Read Panels for high-resolution analysis of HLA genes and other complex genomic regions. In July 2026, GenDx integrated the acquired CareDx laboratory-products portfolio with its HLA typing and transplant-monitoring solutions under Eurobio Scientific ownership, broadening its transplant-focused product catalog and technical-support route.

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and biotechnology.

Access Full Report: https://www.futuremarketinsights.com/reports/precision-transplant-medicine-market

Related Reports:

·         https://sites.google.com/view/healthcarewellnessinsights/prospera-donor-derived-cell-free-dna-transplant-monitoring-market

·         https://sites.google.com/view/healthcarewellnessinsights/outpatient-chemotherapy-free-cancer-treatment-market?read_current=1

·         https://sites.google.com/view/healthcarewellnessinsights/genome-engineering-organ-transplant-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com